Last update 18 Nov 2024

QS Pharma, LLC

Private Company|
2002|
Pennsylvania, United States

Overview

Tags

Neoplasms
Urogenital Diseases
Hemic and Lymphatic Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms4
Nervous System Diseases2
Endocrinology and Metabolic Disease2
Hemic and Lymphatic Diseases1
Immune System Diseases1
Top 5 Drug TypeCount
Small molecule drug6
Top 5 TargetCount
CDK4 x CDK61
Cardiac myosin1
PARP1 x PARP21
RET(Tyrosine-protein kinase receptor RET)1
PI3Kδ(Phosphatidylinositol 3 kinase delta)1

Related

6
Drugs associated with QS Pharma, LLC
Selpercatinib
Target
RET
Mechanism
RET inhibitors
Active Org.
Eli Lilly & Co.Eli Lilly & Co. [+6]
Originator Org.
Loxo Oncology, Inc.Loxo Oncology, Inc.
Active Indication
RET fusion-positive Solid Tumors [+18]
Inactive Indication
Liver Injury
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date08 May 2020
Niraparib Tosylate
Target
PARP1 x PARP2
Mechanism
PARP1 inhibitors [+1]
Active Org.
Takeda Pharmaceutical Co., Ltd.Takeda Pharmaceutical Co., Ltd. [+15]
Originator Org.
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
Active Indication
BRCA-mutated Ovarian Cancer [+80]
Inactive Indication
Advanced Bile Duct Carcinoma [+30]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date27 Mar 2017
Lerociclib
Target
CDK4 x CDK6
Mechanism
CDK4 inhibitors [+1]
Active Org.
Duke UniversityDuke University [+4]
Originator Org.
G1 Therapeutics, Inc.G1 Therapeutics, Inc.
Active Indication
Hormone receptor positive HER2 negative breast cancer [+5]
Inactive Indication
Advanced breast cancer [+4]
Drug Highest PhaseNDA/BLA
First Approval Ctry. / Loc.-
First Approval Date-
11
Clinical Trials associated with QS Pharma, LLC
CTR20241286 / CompletedPhase 1
一项在中国健康受试者中评价BMS-986435（MYK-224）单次给药的安全性、耐受性、药代动力学和药效动力学的随机、双盲、安慰剂对照1 期研究
[Translation] A randomized, double-blind, placebo-controlled Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of BMS-986435 (MYK-224) in healthy Chinese subjects
CTR20233072 / RecruitingNot Applicable
一项评价塞普替尼胶囊（Selpercatinib Capsules）治疗晚期或转移性RET基因融合阳性甲状腺癌（成人和儿童）患者有效性和安全性的（前瞻性、非干预性、）上市后观察性研究
[Translation] A prospective, non-interventional, post-marketing observational study to evaluate the efficacy and safety of selpercatinib capsules in the treatment of advanced or metastatic RET gene fusion-positive thyroid cancer (adults and children)
CTR20213340 / TerminatedPhase 3
一项在骨髓纤维化受试者中评价PI3Kδ抑制剂Parsaclisib联合芦可替尼的III期、随机、双盲、安慰剂对照研究
[Translation] A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kδ Inhibitor Parsaclisib Combined with Ruxolitinib in Subjects with Myelofibrosis
100 Clinical Results associated with QS Pharma, LLC
Login to view more data
0 Patents (Medical) associated with QS Pharma, LLC
Login to view more data
100 Deals associated with QS Pharma, LLC
Login to view more data
100 Translational Medicine associated with QS Pharma, LLC
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1
2
1
Phase 2
Phase 3
2
1
NDA/BLA
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free